Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
An phase I study to evaluate the uptake of [68Ga]P16-093 in known or suspected metastatic
prostate or renal cancer to establish the feasibility of using [68Ga]P16-093 to image PSMA
expressing cancer. Measurement of the whole body biodistribution of [68Ga]P16-093 in prostate
cancer patients post primary curative-intent treatment with stable PSA to generate human
radiation dosimetry data.